Deals and Financings
According to Bloomberg, I-Mab BioPharma (IMAB) of Shanghai is shopping its CD-47 immunoncology candidate to various global biopharmas with hopes of forming a $2 billion collaboration (see story). I-Mab believes TJC4 is a potential global best-in-class CD47 because it binds to a unique epitope on CD47 that leads to only minimal red blood cell binding. In pre-clinical studies, it did not cause anemia, thrombocytopenia or the so-called "antigen sink effect." Like other CD47 candidates, TJC4 works by preventing microphages from being neutralized by the patient's immune system.
Mabwell Biotech, based in